Journal
SMALL
Volume 18, Issue 8, Pages -Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.1002/smll.202104567
Keywords
cancer therapies; in vivo imaging; near-infrared-II windows; quantum dots
Categories
Funding
- National Key Research and Development Program of China [2019YFA0210500]
- National Natural Science Foundation of China [21877102, 21977054, 91859123, 91953107]
Ask authors/readers for more resources
NIR-II imaging breakthrough imaging limitations in deep tissues, while NIR-II quantum dots exhibit excellent optical properties and have become promising fluorescent biomarkers in in vivo fluorescence imaging.
In vivo fluorescence imaging can perform real-time, noninvasive, and high spatiotemporal resolution imaging to accurately obtain the dynamic biological information in vivo, which plays significant roles in the early diagnosis and treatment of cancer. However, traditional in vivo fluorescence imaging usually operates in the visible and near-infrared (NIR)-I windows, which are severely interfered by the strong tissue absorption, tissue scattering, and autofluorescence. The emergence of NIR-II imaging at 1000-1700 nm significantly breaks through the imaging limitations in deep tissues, due to less tissue scattering and absorption. Benefiting from the outstanding optical properties of NIR-II quantum dots (QDs), such as high brightness and good photostability, in vivo fluorescence imaging exhibits excellent temporal-spatial resolution and large penetration depth, and QDs have become a kind of promising fluorescent biomarkers in the field of in vivo fluorescence imaging. Herein, the authors review NIR-II QDs from preparation to modification, and summarize recent applications of NIR-II QDs, including in vivo imaging and imaging-guided therapies. Finally, they discuss the special concerns when NIR-II QDs are shifted from in vivo imaging applications to further in-depth applications.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available